Boon Kua

The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.

Early localisation of disease recurrence after definitive treatment of prostate cancer is vital to determine suitability for salvage treatment. Our aim was to further investigate the relationship between prostate specific antigen (PSA) level and detection of suspected cancer recurrence using 68 Ga‐PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy (RP) or radiotherapy, particularly at low PSA levels.

Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading

In 2012, the International Society of Urological Pathology (ISUP) introduced a novel grading system for clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma. This system is incorporated into the latest World Health Organization renal tumour classification, being designated WHO/ISUP grading. This study was undertaken to compare WHO/ISUP and Fuhrman grading and to validate WHO/ISUP grading as a prognostic parameter in a series of clear cell RCC.

Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma

The aims of this study were to evaluate the impact of tumour‐associated necrosis (TAN) on metastasis‐free survival for clear cell renal cell carcinoma (RCC), and to determine whether TAN provides survival information additional to World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading.

Prostate artery Embolisation Assessment of Safety and feasibilitY (P-EASY): a potential alternative to long-term medical therapy for benign prostate hyperplasia

To assess the safety, short‐term efficacy and early functional results of prostate artery embolisation (PAE), an emerging minimally invasive treatment for symptomatic benign prostate hyperplasia (BPH).

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases

The clinical significance of mucinous prostatic adenocarcinoma (PCa) remains uncertain.

True false negative of MRI scans for prostate cancer screening. How often does MRI miss

Introduction: Ureteric stent placement is oft en associated with morbidity ranging from mild generalised discomfort to signifi cant storage urinary symptoms and loin pain. Our unit identifi ed a high rate of patients re-presenting with side eff ects aft er placement of a ureteric stent. Whilst most re-presentations for common side eff ects only require conservative management they can lead to potentially unnecessary emergency department (ED) consultations, additional investigations and out-of-hours admissions for symptomatic control. All these events result in potentially avoidable increased healthcare costs. Objectives: Prospective single institution audit to assess whether the provision of a written information pamphlet detailing common expected side-eff ects of ureteric stents at the time of discharge in newly stented patients would reduce the rate of re-presentation to hospital related to benign side eff ects and therefore reduce the costs associated with unnecessary emergency room attendances, investigations and occasional hospital admission. Methods: A local stent register was used to identify patients who had ureteric stents inserted 1 year preand post-introduction of the stent information pamphlet. Th e stent information pamphlet was introduced on 5th July 2013. A total of 194 patients had a ureteric stent(s) inserted from 5th July 2012 to 4th July 2013 (Group 1) and a total of 226 patients had a ureteric stent(s) inserted from 5th July 2013 to 5th July 2014 (Group 2). All patients who had ureteric stents inserted during this period were included in the audit, regardless of the initial indication for ureteric stent insertion. Results: Th ere was a 50/194 (25%) and 34/226 (15%) rate of re-presentations preand postimplementation of the stent information pamphlet respectively. Th is refl ected a clinically and statistically signifi cant 10% decrease in the percentage of re-presentations ( P = 0.006) with patients in the pre-implementation group also showing a 1.96 times increased likelihood of re-presenting to hospital (OR = 1.961, 96%CI: 1.206–3.189). Th ere was an average cost saving of

A Cost-Utility Analysis of Prostate Cancer Screening in Australia

899 per ED re-presentation and an additional average cost saving of

Case Report: Radical prostatectomy without prostate biopsy in PI-RADS 5 lesions on 3T multi-parametric MRI of the prostate gland

1936 for each re-presentation resulting in an inpatient stay. Th e reduction in ED re-presentations also released an average of 5.2 h of ED consultation time per patient as well as 23 h of inpatient hospital bed space availability. Conclusions: Ureteric stent information pamphlets resulted in a 10% reduction in hospital re-presentation rates leading to substantial cost savings for the hospital and healthcare system and should therefore be routinely used.